Another emerging approach, potentially with more immediate relevance to patients with DLBCL, uses CAR T cells directed at multiple B‐cell antigens, rather than just CD19, such as CD20 and CD22, which has the potential to improve response by preventing antigen escape.45 The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.